Cargando…

Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design

Varicella-zoster virus (VZV) is a highly infectious agent responsible for both varicella and herpes zoster disease. Despite high efficacy, there remain safety and accessibility concerns with the licensed vaccines. Here, we sought to produce a VZV gE immunogen using an E. coli expression system. We f...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tingting, Sun, Jie, Zhang, Sibo, Li, Tingting, Liu, Liqin, Xue, Wenhui, Zhou, Lizhi, Liang, Siting, Yu, Zhili, Zheng, Qingbing, Yu, Hai, Cheng, Tong, Zhang, Jun, Gu, Ying, Li, Shaowei, Xia, Ningshao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science China Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930067/
https://www.ncbi.nlm.nih.gov/pubmed/36790656
http://dx.doi.org/10.1007/s11427-022-2264-1
_version_ 1784888977484939264
author Chen, Tingting
Sun, Jie
Zhang, Sibo
Li, Tingting
Liu, Liqin
Xue, Wenhui
Zhou, Lizhi
Liang, Siting
Yu, Zhili
Zheng, Qingbing
Yu, Hai
Cheng, Tong
Zhang, Jun
Gu, Ying
Li, Shaowei
Xia, Ningshao
author_facet Chen, Tingting
Sun, Jie
Zhang, Sibo
Li, Tingting
Liu, Liqin
Xue, Wenhui
Zhou, Lizhi
Liang, Siting
Yu, Zhili
Zheng, Qingbing
Yu, Hai
Cheng, Tong
Zhang, Jun
Gu, Ying
Li, Shaowei
Xia, Ningshao
author_sort Chen, Tingting
collection PubMed
description Varicella-zoster virus (VZV) is a highly infectious agent responsible for both varicella and herpes zoster disease. Despite high efficacy, there remain safety and accessibility concerns with the licensed vaccines. Here, we sought to produce a VZV gE immunogen using an E. coli expression system. We found that the soluble expression and yield of gE protein could be enhanced via C-terminal truncations to the protein, thereby facilitating a robust and scalable purification process for the purpose of vaccine manufacturing. The lead truncated gE (aa 31–358), hereafter referred to as tgE, was a homogenous monomer in solution and showed excellent antigenicity. Finally, we assessed and compared the immunogenicity of tgE with commercial vOka LAV and Shingrix vaccine. We found that aluminum-adjuvanted tgE was immunogenic as compared with vOka LAV. When adjuvanted with AS01(B), a two-dose immunization of tgE showed comparable or better potency in antibody responses and cell-mediated immunity with those of the Shingrix vaccine at the same dosage, especially in terms of the proportion of IFN-γ-expressing CD4(+) T cells. In conclusion, this method of E. coli-mediate tgE expression offers a cost-effective and scalable strategy to generate an ideal VZV gE immunogen for the development of both varicella and zoster vaccines.
format Online
Article
Text
id pubmed-9930067
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Science China Press
record_format MEDLINE/PubMed
spelling pubmed-99300672023-02-15 Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design Chen, Tingting Sun, Jie Zhang, Sibo Li, Tingting Liu, Liqin Xue, Wenhui Zhou, Lizhi Liang, Siting Yu, Zhili Zheng, Qingbing Yu, Hai Cheng, Tong Zhang, Jun Gu, Ying Li, Shaowei Xia, Ningshao Sci China Life Sci Research Paper Varicella-zoster virus (VZV) is a highly infectious agent responsible for both varicella and herpes zoster disease. Despite high efficacy, there remain safety and accessibility concerns with the licensed vaccines. Here, we sought to produce a VZV gE immunogen using an E. coli expression system. We found that the soluble expression and yield of gE protein could be enhanced via C-terminal truncations to the protein, thereby facilitating a robust and scalable purification process for the purpose of vaccine manufacturing. The lead truncated gE (aa 31–358), hereafter referred to as tgE, was a homogenous monomer in solution and showed excellent antigenicity. Finally, we assessed and compared the immunogenicity of tgE with commercial vOka LAV and Shingrix vaccine. We found that aluminum-adjuvanted tgE was immunogenic as compared with vOka LAV. When adjuvanted with AS01(B), a two-dose immunization of tgE showed comparable or better potency in antibody responses and cell-mediated immunity with those of the Shingrix vaccine at the same dosage, especially in terms of the proportion of IFN-γ-expressing CD4(+) T cells. In conclusion, this method of E. coli-mediate tgE expression offers a cost-effective and scalable strategy to generate an ideal VZV gE immunogen for the development of both varicella and zoster vaccines. Science China Press 2023-02-09 2023 /pmc/articles/PMC9930067/ /pubmed/36790656 http://dx.doi.org/10.1007/s11427-022-2264-1 Text en © Science China Press 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Research Paper
Chen, Tingting
Sun, Jie
Zhang, Sibo
Li, Tingting
Liu, Liqin
Xue, Wenhui
Zhou, Lizhi
Liang, Siting
Yu, Zhili
Zheng, Qingbing
Yu, Hai
Cheng, Tong
Zhang, Jun
Gu, Ying
Li, Shaowei
Xia, Ningshao
Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design
title Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design
title_full Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design
title_fullStr Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design
title_full_unstemmed Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design
title_short Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design
title_sort truncated glycoprotein e of varicella-zoster virus is an ideal immunogen for escherichia coli-based vaccine design
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930067/
https://www.ncbi.nlm.nih.gov/pubmed/36790656
http://dx.doi.org/10.1007/s11427-022-2264-1
work_keys_str_mv AT chentingting truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT sunjie truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT zhangsibo truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT litingting truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT liuliqin truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT xuewenhui truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT zhoulizhi truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT liangsiting truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT yuzhili truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT zhengqingbing truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT yuhai truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT chengtong truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT zhangjun truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT guying truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT lishaowei truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign
AT xianingshao truncatedglycoproteineofvaricellazostervirusisanidealimmunogenforescherichiacolibasedvaccinedesign